TO901317 inhibits the migration of MCF-7 breast cancer cells through LXRα/NF-κB
Objective To explore the effect and mechanism of liver X receptor(LXR)agonist TO901317 on the migration ability of MCF-7 human breast cancer cells.Methods MCF-7 cells were cultured in vitro.At first,MCF-7 cells were treated with TO901317 with different concentrations for 24 h,and then the cells were transfected with LXRα siRNA or treated with PDTC,a nuclear factor κB(NF-κB)inhibitor.The changes of migration ability of MCF-7 cells were detected by scratch healing experiment,and the expressions of LXRα,NF-κB p65 and IκBα were detected by Western blot.Results With the increase of TO901317 concentration,the migration ability of MCF-7 cells was obviously inhibited,and the difference was statistically significant(P<0.05).At the same time,the expressions of LXRα and IκBα increased gradually,while the expression of NF-κB p65 decreased significantly.LXRα siRNA can significantly delay the above-mentioned effects of TO901317,and PDTC treatment can further enhance the inhibitory effect of TO901317 on breast cancer cell migration.Conclusion TO901317 can activate LXRα,down-regulate NF-κB p65,up-regulate the expression of IκBα,and inhibit the migration of breast cancer cells.
TO901317liver X receptor αNF-κBMCF-7 breast cancer cellscell migration
NETL
NSTL
万方数据
